A first-in-class approval that mattered
Severe alopecia areata — autoimmune hair loss with patchy or total scalp coverage — affected approximately 170,000 Korean patients receiving hospital treatment in 2021. Before 2023, no systemic medication was approved for this condition. Treatments were limited to corticosteroid injections, topical immunomodulators, and contact sensitizers, all with limited evidence for severe cases.
Korea\'s Ministry of Food and Drug Safety (MFDS) approved Olumiant (baricitinib), Eli Lilly\'s JAK inhibitor, for severe alopecia areata in March 2023 — making it Korea\'s first systemic alopecia areata drug. By 2026, the prescribing protocol is established, dermatology clinics across Gangnam offer the treatment, and Korean patients have access at significantly lower cost than US equivalents.
What baricitinib actually does
Baricitinib is a Janus kinase (JAK) inhibitor — it blocks the JAK1 and JAK2 enzymes that drive autoimmune signaling cascades. In alopecia areata, the immune system inappropriately attacks hair follicles. JAK inhibition interrupts this attack, allowing follicles to recover and regrow hair.
Mechanism details:
- Blocks JAK1/JAK2 enzymes
- Interrupts interferon-gamma signaling that activates follicle attack
- Allows damaged follicles to resume normal cycle
- Effect: meaningful hair regrowth in 40–50% of patients within 36 weeks
- Continued treatment maintains regrowth; discontinuation typically results in hair loss recurrence
Who is eligible in Korea
Korean MFDS approval criteria:
- Age 18 or older
- Severe alopecia areata (SALT score 50+ — at least 50% scalp hair loss)
- Failed conventional treatments
- No active infections
- No significant liver or kidney disease
- Negative tuberculosis screening
- Acceptable cardiovascular risk profile
The clinical trial evidence
The BRAVE-AA1 and BRAVE-AA2 phase 3 trials supported approval. Korea participated in both trials. Key findings:
- ~40% of patients achieved SALT ≤20 (80%+ scalp coverage) at 36 weeks at 4mg dose
- ~20% achieved this result at 2mg dose
- Hair regrowth started visibly at week 16 in responders
- Maximum effect at week 36, continued improvement to week 52
Treatment protocol in Korean dermatology
Pre-treatment workup
- Complete blood count and metabolic panel
- Liver function tests
- Lipid panel
- Tuberculosis screening (interferon-gamma release assay)
- Hepatitis B and C screening
- Pregnancy test for female patients
- Vaccination status review (live vaccines contraindicated during treatment)
Dosing
- Standard adult starting dose: 4 mg daily oral
- Maintenance: continue 4 mg if responsive, reduce to 2 mg for some patients
- Minimum trial period: 36 weeks before assessing response
- Discontinuation: gradual taper if stopping treatment
Monitoring schedule
- Monthly blood tests for first 3 months
- Quarterly thereafter
- Cardiovascular event monitoring
- Infection screening before/during treatment
- Hair coverage assessment every 12 weeks
Cost in Korea (2026)
- Monthly medication cost: ₩400,000–600,000 ($300–450) — partially insurance-covered for eligible diagnoses
- Dermatology consultation: ₩60,000–150,000 per visit
- Monthly blood tests: ₩50,000–100,000
- Annual treatment total: ₩6,000,000–10,000,000 ($4,500–7,500)
US monthly cost without insurance: $4,000–6,000. Korean prescription is dramatically more affordable but international patients must verify their home country\'s import regulations.
Realistic results timeline
- Weeks 1–8: no visible change yet
- Weeks 12–16: subtle hair growth starting in some patients
- Weeks 24–36: visible coverage improvement in responders
- Week 52: maximum response achieved
- Continued treatment: maintains result
- Discontinuation: most patients lose regrowth over 6–12 months
Side effects and risks
Common (5–15%)
- Upper respiratory infections
- Headache
- Increased cholesterol
- Mild acne
- Elevated liver enzymes
Less common but serious
- Serious infections (especially in immunocompromised patients)
- Tuberculosis reactivation
- Herpes zoster (shingles) reactivation
- Blood clots (deep vein thrombosis, pulmonary embolism)
- Cardiovascular events in high-risk patients
- Increased cancer risk (very rare)
Who should consider Olumiant
- Severe alopecia areata with significant psychosocial impact
- Failed conventional therapies
- Age 18+
- Good general health
- Willing to commit to long-term treatment
- Acceptable monitoring compliance
Who should not
- Active or recurrent infections
- Pregnancy or planned pregnancy
- Active malignancy
- Severe liver or kidney disease
- History of blood clots
- Significant cardiovascular disease
- Patients seeking short-term treatment (effect requires sustained use)
Other JAK inhibitors in Korean treatment landscape
Olumiant is not the only option. Korean dermatology in 2026 also uses:
- Litfulo (ritlecitinib): approved 2024, JAK3/TEC inhibitor
- Topical ruxolitinib: for milder cases and adjunct therapy
- Tofacitinib (off-label): older JAK inhibitor, occasionally used
Most Korean dermatologists start with Olumiant for severe cases unless specific contraindications exist.
The 2026 patient experience
Korean dermatology clinics offering Olumiant typically:
- Run dedicated alopecia clinics (separate from general derm)
- Provide telemedicine follow-up between in-person visits
- Offer financing programs for monthly medication costs
- Coordinate with psychiatric support for the psychosocial impact of alopecia areata
- Connect patients to support communities
For international patients
- Initial consultation can be conducted in Korea
- Many patients establish Korean prescription, then continue follow-up via teleconsultation
- Medication shipping varies by home country regulations
- Korean prescription typically requires in-Korea visits at minimum quarterly
- Travel insurance does not cover alopecia areata treatment
Honest framing
Baricitinib represents real medical progress for a condition that previously had no effective systemic treatment. The Korean availability and pricing makes this treatment significantly more accessible than in many Western countries. The drug works in roughly half of severe patients — not all patients respond, and prediction tools for responders remain limited. The commitment is long-term: discontinuation typically returns the patient to pre-treatment hair loss state. Patients considering Olumiant should be honest about the lifelong nature of treatment, the monitoring requirements, and the risk profile. For the right patient — severe alopecia areata significantly affecting quality of life — Olumiant is the most effective option available in 2026. For mild or moderate cases, conventional treatments remain appropriate.